{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:29:30Z","timestamp":1789831770134,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaip.2022.02.014","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T04:05:14Z","timestamp":1645502714000},"page":"1534-1544.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use"],"prefix":"10.1016","volume":"10","author":[{"given":"David J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Nanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamsin","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabada","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.02.014_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.014_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.02.014_bib3","first-page":"A4525","article-title":"Characterization of eosinophilic and non-eosinophilic severe asthma phenotypes and proportion of patients with these phenotypes in the International Severe Asthma Registry (ISAR)","volume":"201","author":"Perez-de-Llano","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: An expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.02.014_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.02.014_bib7","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.014_bib8","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.02.014_bib9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.202003-0729LE","article-title":"Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma","volume":"202","author":"Moran","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib10","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"for the ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2022.02.014_bib12","article-title":"UK Severe Asthma Registry. Factors associated with frequent exacerbations in the UK Severe Asthma Registry","volume":"9","author":"Yang","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.014_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.014_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-3-58","article-title":"Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older","volume":"3","author":"Juniper","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaip.2022.02.014_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.02.014_bib16","first-page":"2250","article-title":"Phenotyping mepolizumab exacerbations in severe eosinophilic asthma (MEX)","volume":"56","author":"McDowell","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.014_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib19","doi-asserted-by":"crossref","first-page":"1901633","DOI":"10.1183\/13993003.01633-2019","article-title":"Clinical utility of fractional exhaled nitric oxide (FeNO) in severe asthma management","volume":"55","author":"Menzies-Gow","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.014_bib20","first-page":"OA3807","article-title":"Dupilumab efficacy in type 2 inflammatory asthma: Liberty Asthma QUEST Study","volume":"54","author":"Pavord","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.02.014_bib21","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.014_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbations rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/JAA.S190221","article-title":"Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma","volume":"12","author":"O\u2019Quinn","year":"2019","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.02.014_bib24","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Delphi panel. Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.014_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-019-1134-7","article-title":"Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight\/body mass index: meta-analysis of MENSA and MUSCA","volume":"20","author":"Albers","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2022.02.014_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.02.014_bib27","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1513\/AnnalsATS.201901-071OC","article-title":"Placebo effects in clinical trials evaluating patients with uncontrolled persistent asthma","volume":"16","author":"Luc","year":"2019","journal-title":"Ann Am Thor Soc"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:33:58Z","timestamp":1761975238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2213219822001416"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.014","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}